Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M. Ito T, et al. Among authors: kondo s. Invest New Drugs. 2013 Oct;31(5):1265-74. doi: 10.1007/s10637-012-9910-y. Epub 2012 Dec 27. Invest New Drugs. 2013. PMID: 23269537 Free PMC article. Clinical Trial.
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Ikeda M, Shiina S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Ueno H, Morizane C, Kondo S, Sakamoto Y, Asaoka Y, Tateishi R, Koike K, Arioka H, Okusaka T. Ikeda M, et al. Among authors: kondo s. Invest New Drugs. 2014 Oct;32(5):928-36. doi: 10.1007/s10637-014-0109-2. Epub 2014 May 15. Invest New Drugs. 2014. PMID: 24829073 Free PMC article. Clinical Trial.
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N. Fujiwara Y, et al. Among authors: kondo s. Cancer Chemother Pharmacol. 2016 Aug;78(2):281-8. doi: 10.1007/s00280-016-3085-8. Epub 2016 Jun 16. Cancer Chemother Pharmacol. 2016. PMID: 27312735 Clinical Trial.
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Yamamoto N, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Tanabe Y, Horiike A, Yanagitani N, Kitazono S, Inatani M, Tanaka J, Nishio M. Yamamoto N, et al. Among authors: kondo s. Invest New Drugs. 2017 Feb;35(1):37-46. doi: 10.1007/s10637-016-0382-3. Epub 2016 Aug 27. Invest New Drugs. 2017. PMID: 27565810 Clinical Trial.
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Ikeda M, Ohno I, Ueno H, Mitsunaga S, Hashimoto Y, Okusaka T, Kondo S, Sasaki M, Sakamoto Y, Takahashi H, Hara R, Kobayashi S, Nakamura O, Morizane C. Ikeda M, et al. Among authors: kondo s. Invest New Drugs. 2019 Feb;37(1):109-117. doi: 10.1007/s10637-018-0634-5. Epub 2018 Jul 11. Invest New Drugs. 2019. PMID: 29995287 Clinical Trial.
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M. Shimomura A, et al. Among authors: kondo s. Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24. Mol Cancer Ther. 2019. PMID: 30679388 Clinical Trial.
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Ebata T, Shimizu T, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Yonemori K, Shimomura A, Kitano S, Koyama T, Sato N, Nakai K, Inatani M, Yamamoto N. Ebata T, et al. Among authors: kondo s. Invest New Drugs. 2020 Apr;38(2):468-477. doi: 10.1007/s10637-019-00787-3. Epub 2019 May 24. Invest New Drugs. 2020. PMID: 31124055 Free PMC article. Clinical Trial.
3,719 results